Exelbine vinorelbine emulsion regulatory update

Adventrx resubmitted an NDA to FDA for Exelbine vinorelbine injectable emulsion to treat non-small cell lung cancer (NSCLC). Adventrx said the submission included 12 months of site-specific stability ...